secwatch / observer
8-K filed February 15, 2023, 6:59 PM ET ticker OSRH CIK 0001840425
other material confidence high sentiment neutral materiality 0.50

SPAC Bellevue Life Sciences closes $60M IPO; $61.05M in trust, 9-month deadline for healthcare deal

OSR Holdings, Inc.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

OSR Holdings, Inc.: Filed Amended and Restated Certificate of Incorporation on February 13, 2023 (effective 2023-02-13).

Change
charter amendment
Effective
2023-02-13
Exact text from the filing
On February 13, 2023, the Company filed an Amended and Restated Certificate of Incorporation with the Secretary of the State of Delaware.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OSR Holdings, Inc. entered into Underwriting Agreement with Chardan Capital Markets, LLC valued at $60.0 million (effective 2023-02-09).

Action
entry
Agreement
underwriting
Counterparty
Chardan Capital Markets, LLC
Value
$60.0 million
Effective
2023-02-09
Exact text from the filing
On February 9, 2023, Bellevue Life Sciences Acquisition Corp., a Delaware corporation (the “Company”), entered into an underwriting agreement by and between the Company and Chardan Capital Markets, LLC (“Chardan”), as representative of the several underwriters named therein (collectively, the “Underwriters”), a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference (the “Underwriting Agreement”), relating to the Company’s initial public offering (the “Offering”) of 6,000,000 units (the “Units”) at a price to the public of $10.00 per Unit.
View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

OSR Holdings, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-040219
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.